The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years

Autor: Enrico Maria Pogliani, Gianmarco Corneo, Rocco Piazza, Anna Franceschino, Lucia Tornaghi, Carlo Gambacorti-Passerini, Vera Magistroni, Federica Colnaghi, Federica Andreoni
Přispěvatelé: Piazza, R, Magistroni, V, Franceschino, A, Andreoni, F, Tornaghi, L, Colnaghi, F, Corneo, G, Pogliani, E, GAMBACORTI PASSERINI, C
Jazyk: angličtina
Rok vydání: 2006
Předmět:
Oncology
Predictive Value of Test
Drug resistance
Single Center
Piperazines
Cohort Studies
Recurrence
hemic and lymphatic diseases
Medicine
Reverse Transcriptase Polymerase Chain Reaction
Remission Induction
Myeloid leukemia
Cytogenetic Analysi
Hematology
Middle Aged
Survival Rate
Treatment Outcome
Predictive value of tests
Data Interpretation
Statistical
Benzamides
Cytogenetic Analysis
Imatinib Mesylate
Molecular Medicine
medicine.drug
Human
Adult
medicine.medical_specialty
Drug Administration Schedule
Time
Follow-Up Studie
Predictive Value of Tests
Internal medicine
Leukemia
Myelogenous
Chronic
BCR-ABL Positive
Humans
neoplasms
Molecular Biology
Survival rate
Piperazine
Aged
business.industry
Imatinib
Cell Biology
medicine.disease
Surgery
Imatinib mesylate
Pyrimidines
Pyrimidine
Cohort Studie
business
Progressive disease
Follow-Up Studies
Popis: Despite the positive results achieved by Imatinib mesylate (Imatinib) in the treatment of chronic myeloid leukemia (CML), over the past several years, Imatinib does not eradicate the leukemic clone. The long-term duration of response to the drug is not known. Long-term follow-up of CML patients treated with Imatinib will ultimately define the durability of such treatment and the frequency of reemergence of progressive disease. We present the results of a 6-year follow-up of 40 CML patients either in chronic or accelerated phase who obtained a durable (> 6 months) complete cytogenetic remission (CCyR) after treatment with Imatinib in a single center. In 34 cases CCyR was obtained at an Imatinib dose of 400–600 mg/day and in 6 cases after a dose increase to 600–800 mg/day. At a median follow-up of 68 months, 6 cytogenetic relapses (15%) were observed. No progressions to more advanced phases of disease have been detected during the follow-up period. Cytogenetic relapse was predicted by either a decrease in the amount of BCR-ABL transcript of less than 2 logs after the achievement of CCyR ( p = 0.0041) or a time-to-CCyR of more than 12 months ( p This 6-year follow-up of the efficacy of Imatinib therapy in CML patients who obtained a durable CCyR indicates that the relapses rate is low over this period of observation and that the rate of relapse does not increase over time.
Databáze: OpenAIRE
Externí odkaz: